AU2001269726A1 - Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers - Google Patents

Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers

Info

Publication number
AU2001269726A1
AU2001269726A1 AU2001269726A AU6972601A AU2001269726A1 AU 2001269726 A1 AU2001269726 A1 AU 2001269726A1 AU 2001269726 A AU2001269726 A AU 2001269726A AU 6972601 A AU6972601 A AU 6972601A AU 2001269726 A1 AU2001269726 A1 AU 2001269726A1
Authority
AU
Australia
Prior art keywords
methods
kiaa0175
compositions
chemotherapy
treating neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269726A
Inventor
Todd W. Seeley
Lewis T. Williams
Bin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001269726A1 publication Critical patent/AU2001269726A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and/or p21 gene expression as well as methods for increasing the chemo and/or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.
AU2001269726A 2000-05-31 2001-05-30 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers Abandoned AU2001269726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20843500P 2000-05-31 2000-05-31
US60/208,435 2000-05-31
PCT/US2001/017644 WO2001091739A2 (en) 2000-05-31 2001-05-30 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers

Publications (1)

Publication Number Publication Date
AU2001269726A1 true AU2001269726A1 (en) 2001-12-11

Family

ID=22774595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269726A Abandoned AU2001269726A1 (en) 2000-05-31 2001-05-30 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers

Country Status (10)

Country Link
US (2) US6974867B2 (en)
EP (1) EP1292289B1 (en)
JP (1) JP2003534786A (en)
AT (1) ATE387909T1 (en)
AU (1) AU2001269726A1 (en)
CA (1) CA2410516A1 (en)
DE (1) DE60133104T2 (en)
ES (1) ES2299493T3 (en)
PT (1) PT1292289E (en)
WO (1) WO2001091739A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335636D1 (en) * 2002-09-11 2011-02-17 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
US7879545B2 (en) * 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
JP5028601B2 (en) * 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 Breast cancer-related genes and polypeptides
US20090163406A1 (en) * 2004-09-30 2009-06-25 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
JP2010539890A (en) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ Genetic signature for predicting response to radiation therapy
TWI466680B (en) 2008-08-01 2015-01-01 Oncotherapy Science Inc Melk epitope peptides and vaccines containing the same
TWI485245B (en) 2010-01-25 2015-05-21 Oncotherapy Science Inc Modified melk peptides and vaccines containing the same
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
SI3221457T1 (en) 2014-11-21 2019-08-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
JP4320054B2 (en) 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Compositions and methods for polynucleotide delivery
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
ES2302699T3 (en) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. ANTISENTIDE CHEMICAL OLIGONUCLEOTIDES AND CELLULAR TRANSFECTION FORMULATIONS OF THE SAME.

Also Published As

Publication number Publication date
ES2299493T3 (en) 2008-06-01
US20020049180A1 (en) 2002-04-25
US6974867B2 (en) 2005-12-13
WO2001091739A3 (en) 2003-01-16
US20050282766A1 (en) 2005-12-22
JP2003534786A (en) 2003-11-25
WO2001091739A2 (en) 2001-12-06
PT1292289E (en) 2008-04-23
DE60133104T2 (en) 2009-03-12
CA2410516A1 (en) 2001-12-06
DE60133104D1 (en) 2008-04-17
ATE387909T1 (en) 2008-03-15
EP1292289B1 (en) 2008-03-05
EP1292289A2 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
AU2001269726A1 (en) Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
ATE545699T1 (en) MODIFIED RECOMBINANT VACCINIA VIRUSES AND USES THEREOF
SG170080A1 (en) Human monoclonal antibodies to o8e
RU94045281A (en) Immunoconjugates, method of preparing immunoconjugate, pharmaceutical composition, use of immunoconjugate
Kim et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer
NO2007014I2 (en) Anti-VEGF antibody, composition, nucleic acid, vector, host cell, method and drug for medical use
EP1137658A4 (en) METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
BRPI0412637A (en) antibodies, hvegf antibody selection method, isolated nucleic acid, vector, host cell, antibody production process, antibody use method and treatment method of a mammal
CY1106991T1 (en) ANTIPLIPLASPULATING PROPERTIES OF Gene Oligonucleotides and Their Method of Use
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
PT1383785E (en) Recombinant tumor specific antibody and use thereof
DE602006012667D1 (en) FUSION PROTEIN OF ANTIBODY L19 AGAINST FIBRONECTIN ED-B AND INTERLEUKIN 12
Counsell et al. Efficient and selective antibody modification with functionalised divinyltriazines
MX9801264A (en) Control of cd44 gene expression for therapeutic use.
WO2007055966A3 (en) Therapies for cancer using rlip76
Marsh et al. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis
DE50009365D1 (en) MEANS OF TREATMENT OF MALIGNER DISEASES USING THE PROTEIN YB-1
Davies et al. Hyperthermia-induced changes in antigen expression on human FME melanoma cells
MX2021008453A (en) Formulations of antibodies that bind human cd137 and uses thereof.
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
Dai et al. Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine
WO2003032899A3 (en) Methods and materials for targeting and affecting selected cells
WO2002006340A3 (en) Tetraspan protein and uses thereof